Aspirgillosis is a deadly fungal infection that is a major cause of mortality in patients with impaired immune systems. The current standard of care has been voriconazole due to the favorable side effect profile compared to amphotericin. However, posaconazole may not have there adverse effects and be a reasonable course of therapy. Is voriconazole just just a phase?Today's episode is sponsored by a special CEimpact FREE Law focused webinar: Save your spot - FREE LIVE LAW CEwebinar on April 1st.  SPOTS ARE LIMITED!https://ceimpact.com/law Reference: Maertens JA, Rahav G, Lee DG, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021 Feb 6;397(10273):499-509. doi: 10.1016/S0140- 6736(21)00219-1. PMID: 33549194.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America, Clinical Infectious Diseases, Volume 63, Issue 4, 15 August 2016, Pages e1–e60, hMps://doi.org/10.1093/cid/ciw326CPE details for GameChangers Podcast March 2021Learning Objective: Develop appropriate treatment of aspergillosis infections based on clinical studies.0107-0000-21-097-H01-P0.25 CEU/2.5 Hrs (Knowledge)Initial Release Date: 03/02/21Expiration Date: 03/02/24Additional CPE information is located at https://www.ceimpact.com/podcastSee omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The recently published STEP trial showed a dramatic effect on weight loss with the weekly injectable semaglutide versus placebo. Lay media picked up the headlines from this potential "GameChanger" medication for weight loss. With this one shot will patient lose themselves?Reference: Wilding J, Batterham R, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. February 10, 2021. DOI: 10.1056/NEJMoa2032183CPE details for GameChangers Podcast March 2021Learning Objective: Discuss the design of the STEP trial0107-0000-21-097-H01-P0.25 CEU/2.5 Hrs (Knowledge)Initial Release Date: 03/02/21Expiration Date: 03/02/24Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The endocannabinoid system is influenced by compounds found the Cannabis genus of plants and involves two compounds: cannabidiol (CBD) and tetrahydrocannabinol (THC). Federal and state regulation is changing, so the medicinal and recreatoinal use of cannabis-related prodcuts continues to increase. Although not life-threatening, some patients may experience Cannabis Hyperemesis Syndrome. Fortunately, a narrative review outlines the causes and treatment to help get out the weeds of treatment.Reference: Perisetti A, Gajendran M, Dasari C, et al. Cannabis hyperemesis syndrome: an update on the pathophysiology and management. Annals of Gastroenterology (2020) 33, 1-8. http://www.annalsgastro.gr/files/journals/1/earlyview/2020/ev-09-2020-01-AG_5230-0528.pdf CPE details for GameChangers Podcast March 2021Learning Objective: Describe the potential mechanisms and treatment options for Cannabis Hyperemesis Syndrome.0107-0000-21-097-H01-P0.25 CEU/2.5 Hrs (Knowledge)Initial Release Date: 03/02/21Expiration Date: 03/02/24Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The recently published (in a pre-print server) COLCORONA study, sponsored by the Montreal Heart institute and conducted in 6 countries aimed to show if using colchicine would decrease risk of hospitalization and death in outpatients with COVID-19. Will it work? How's the study design? Learn the facts.Reference: Tardif J, Bouabdallaoui N, L'Allier P, et al. Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19. Pre-Print. https://www.medrxiv.org/content/10.1101/2021.01.26.21250494v1CPE details for GameChangers Podcast March 2021Learning Objective: Apply the results of the CORCORONA study to patients with COVID-19 disease.0107-0000-21-097-H01-P0.25 CEU/2.5 Hrs (Knowledge)Initial Release Date: 03/02/21Expiration Date: 03/02/24Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The United States Preventative Services Task Force (USPSTF) recommendations for tobacco cessation have been recently updated. While no major changes to pharmacotherapy recommendations are in the new guidelines, the paper does emphasize that all health care providers can work with patients to help them achieve tobacco freedom. Learn how to support patients in your community.Reference: USPSTF Recommendation: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions CPE details for GameChangers Podcast February 2021Learning Objective: Discuss the rates of tobacco cessation and adverse effects of current Food and Drug Administration approved therapy for tobacco cessation.0107-0000-21-083-H01-P0.2 CEU/2.0 Hrs (Knowledge)Initial Release Date: 02/23/21Expiration Date: 02/23/24Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The National Asthma Education and Prevention Program released the 2020 Asthma Guideline Update in December 2020. This guideline, published in JAMA, is different from the internal Global Initative for Asthma (GINA) guidelines and represents the first update since 2007. Learn about what makes these guidelines unique and how healthcare providers can maintain breaths.This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!Reference: Commentary: Cloutier MM, Dixon AE, Krishnan JA, Lemanske RF, Pace W, Schatz M. Managing Asthma in Adolescents and Adults: 2020 Asthma Guideline Update From the National Asthma Education and Prevention Program. JAMA. 2020;324(22):2301–2317. doi:10.1001/jama.2020.21974 Guidelines: 2020 Focused Updates to the Asthma Management Guidelines. https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines CPE details for GameChangers Podcast February 2021Learning Objective: Describe recommended therapy based on the staging on asthma in individuals 12 years or olderGuest Faculty: Kelli Cunningham, PharmD, BCPSDr. Cunningham reports no actual or potential conflicts of interest in relation to this episode of GameChangers.0107-0000-21-083-H01-P0.2 CEU/2.0 Hrs (Knowledge)Initial Release Date: 02/23/21Expiration Date: 02/23/24Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Irritable bowel syndrome is a common disorder that exacts a significant toll on quality of life. For the first time, the American College of Gastroenterology has published guidelines on the diagnosis and treatment for this disorder.This episode is accredited for CPE. Subscribe at CEimpact( https://www.ceimpact.com/pharmacist ) and claim your CE today!Reference: Lacy, Brian E. PhD, MD, FACG1; Pimentel, Mark MD, FACG2; Brenner, Darren M. MD, FACG3; Chey, William D. MD, FACG4; Keefer, Laurie A. PhD5; Long, Millie D. MDMPH, FACG (GRADE Methodologist)6; Moshiree, Baha MD, MSc, FACG7 ACG Clinical Guideline: Management of Irritable Bowel Syndrome, The American Journal of Gastroenterology: January 2021 - Volume 116 - Issue 1 - p 17-44 doi: 10.14309/ajg.0000000000001036.Accessed at https://journals.lww.com/ajg/Fulltext/2021/01000/ACG_Clinical_Guideline__Management_of_Irritable.11.aspx Bristol stool scale (recommend tertiary references): Lewis, SJ; Heaton, KW (September 1997). "Stool form scale as a useful guide to intestinal transit time". Scand. J. Gastroenterol. 32 (9): 920–4. doi:10.3109/00365529709011203. PMID 9299672.CPE details for GameChangers Podcast February 2021Learning Objective: Discuss appropriate treatments for irritable bowel syndrome0107-0000-21-083-H01-P0.2 CEU/2.0 Hrs (Knowledge)Initial Release Date: 02/23/21Expiration Date: 02/23/24Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Lyme disease is a complex infection and post infection syndrome can lead to serious outcomes, including death. A new guideline was developed for the diagnosis and treatment of this infection. Spoon!This episode is accredited for CPE. Subscribe at CEimpact( https://www.ceimpact.com/pharmacist ) and claim your CE today!Reference: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clinical Infectious Diseases, November 30, 2020. https://doi.org/10.1093/cid/ciaa1215. Accessed athttps://www.idsociety.org/practice-guideline/lyme-disease/ CPE details for GameChangers Podcast February 2021Learning Objective: Discuss treatment for different forms of lyme disease infections depending on the severity of symptoms0107-0000-21-XXX-H01-P0.2 CEU/2.0 Hrs (Knowledge)Initial Release Date: 02/23/21Expiration Date: 02/23/24Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

In December 2020, the American College of Cardiology published an Expert Consensus Decision Pathway for Antithrombotic Therapy in Patients undergoing Percutaneous Coronary Intervention. This guideline addresses a timely problem of patients on anticoagulation and antiplatelet therapy.This episode is accredited for CPE. Subscribe at CEimpact ( https://www.ceimpact.com/pharmacist ) and claim your CE today!Reference: 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. Dec 18, 2020. Epublished DOI: 10.1016/j.jacc.2020.09.011. Accessed at https://www.jacc.org/doi/10.1016/j.jacc.2020.09.011CPE details for GameChangers Podcast January 2021Learning Objective: Recommend an appropriate antithrombotic/anticoagulant regimen in a patient who has received percutaneous coronary intervention with stenting0107-0000-21-079-H01-P0.2 CEU/2.0 Hrs (Knowledge)Initial Release Date: 01/25/21Expiration Date: 01/26/24Additional CPE information is located at https://www.ceimpact.com/podcastSee omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The unbelievable happened in 2020 - a vaccine was developed with high efficacy within 12 months for a novel virus! In December two vaccines for the prevention of the SARS-CoV-2 virus were approved through Emergency Use Authorization in the US. Is it time to get a shot?This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!Reference: Polack F, Thomas S, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. NEJM. Dec 10, 2020. DOI: 10.1056/NEJM2034577Baden L, El Sahly H, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. NEJM. Dec 30, 2020. DOI: 10.1056/NEHMoa2035389ACIP Recommendations: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram